MXCT.L - MaxCyte, Inc.

LSE - LSE Delayed Price. Currency in GBp
0.00 (0.00%)
At close: 4:30PM GMT
Stock chart is not supported by your current browser
Previous Close240.00
Bid0.00 x 250000
Ask0.00 x 150000
Day's Range240.95 - 240.95
52 Week Range133.63 - 300.00
Avg. Volume5,195
Market Cap122.107M
PE Ratio (TTM)N/A
EPS (TTM)-14.20
Earnings DateSep 25, 2017 - Sep 29, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.54
  • Capital Cubelast month

    MaxCyte, Inc. :MXCT-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 2, 2017

    Categories: Yahoo FinanceGet free summary analysis MaxCyte, Inc. reports financial results for the half-year ended June 30, 2017. Highlights Summary numbers: Revenues of GBP 4.93 million, Net Earnings of GBP -3.41 million. Gross margins widened from 89.54% to 89.55% compared to the same period last year, operating (EBITDA) margins now -63.27% from -15.94%. Earnings rose compared to ... Read more (Read more...)

  • Capital Cube2 months ago

    MaxCyte, Inc. – Value Analysis (LONDON:MXCT) : October 27, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives MaxCyte, Inc. a score of 47. Our analysis is based on comparing MaxCyte, Inc. with the following peers – NetScientific plc, Oxford BioDynamics PLC, Oncimmune Holdings Plc and Oryzon Genomics SA (NSCI-GB, OBD-GB, ONC-GB and ORY-ES). Investment Outlook MaxCyte, Inc. has a fundamental score of 47 and ... Read more (Read more...)

  • We're sorry this is all we were able to find about this topic.